| Name | Title | Contact Details |
|---|
C5 MedicalWerks is a Grand Junction, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Only Amedica has developed the technology to create medical grade silicon nitride ceramic; a material that, compared to others on the market, promises spinal implants with excellent osteoconductive properties, higher wear resistance, and greatly improved compatibility with MRI, fluoroscopy and CT imaging systems.
The West Wireless Health Institute is one of the first medical research organizations in the world supporting the exploration and application of wireless technologies to advance infrastructure independent health care.
At CareFusion, we are united in our vision to improve the safety and lower the cost of healthcare for generations to come. Our 16,650 worldwide employees are passionate about healthcare and helping those that deliver it - from the hospital pharmacy to the intensive care unit, the operating theatre to the patient bedside and beyond. Our proven product families include Intermed, AVEA, VELA, SensorMedics, AirLife and respiratory products, Pyxis automated dispensing and patient identification systems, V. Mueller and Snowden-Pencer surgical instruments, Achieve Temno and Jamshidi, and the PleurX drainage system and the Alaris IV pumps (not sold in Brazil). To make global healthcare better, we partner with our customers to provide clinically differentiated respiratory solutions to help optimize patient care, improve medication management and lower the cost in procedural areas.
OXiGENE is a biopharmaceutical company developing new and improved therapeutics that have the potential to deliver significant medical benefits to patients with cancer and serious medical conditions. Our primary focus is developing first-in-class anti-vascular drugs referred to as vascular disrupting agents (VDAs). Our lead compound in clinical development is fosbretabulin. VDAs are a new and highly differentiated class of anti-vascular drug that target existing tumor vasculature, leading to extensive tumor cell death. VDAs target the tumor vasculature rather than the tumor cells and therefore have broad potential therapeutic utility in cancer. Because VDAs act differently than anti-angiogenic drugs or cytotoxic chemotherapy drugs, VDAs are potentially complementary with anti-angiogenic drugs and chemotherapeutic agents. OXiGENE has ongoing VDA drug development programs and is committed to advancing the science of VDAs and their potential as innovative therapies to address unmet medical needs.